KIT and gastrointestinal stromal tumor: Inhibiting c-KIT activity with longer-term imatinib treatments promoted RACK1 expression via disruptions in the ubiquitin-proteasome pathway, and RACK1 was highly expressed in imatinib-resistant GIST cell lines and recurrent GIST tissues.